ENHANCE-Efficacy of the Presence of Right Ventricular Apical Pacing Induced Ventricular Dyssynchrony as a Guiding Parameter for Biventricular Pacing in Patients With Bradycardia and Normal Ejection Fraction — ENHANCE

Bradycardia Clinical Trial

Official title:
Efficacy of the Presence of Right Ventricular Apical Pacing Induced Ventricular Dyssynchrony as a Guiding Parameter for Biventricular Pacing in Patients With Bradycardia and Normal Ejection Fraction

Status Completed

Clinical Trial Summary

The purpose of this clinical project is to evaluate the efficacy of the presence of Right Ventricular Apical (RVA) pacing induced ventricular dyssynchrony as a guiding parameter for bi-ventricular pacing in patients with bradycardia and normal left ventricular ejection fraction (LVEF). The results of this project may provide with the evidence based medicine for guidelines expansion of using Cardiac resynchronization therapy (CRT) in patients with Heart Block and normal LVEF (LVEF >45%).

Clinical Trial Description

All eligible patients willing to provide written informed consent were invited to participate in the study, and then randomized 1:2 to either the Control Group or Echo-guided Group. Patients randomized into the Control Group were implanted with a dual chamber pacemaker (DDDR) device (St. Jude Medical) standard therapy. Patients randomized into the Echo-guided Group were implanted with a cardiac resynchronization therapy pacemaker (CRT-P) device (St. Jude Medical), which was programmed to DDDR pacing mode (CRT-P OFF) at implant. For each Echo-guided Group patient, presence of RVA pacing induced ventricular dyssynchrony was assessed within 24-hour of implant using the standardized criteria of Doppler echocardiography. The Echocardiography Core Laboratory (Echo Core Lab) then analyzed each image and the treatment allocation of the Echo-guided Group was done within 72-hour post implant based on the Echo Core Lab outcomes:

- Patients with the presence of RVA pacing induced ventricular dyssynchrony were allocated to the CRT-P standard therapy with CRT-P turned ON

- Patients with the absence of RVA pacing induced ventricular dyssynchrony were allocated to the DDDR standard therapy with CRT-P remained OFF

Patients meeting all the inclusion criteria and not meeting any of the exclusion criteria were eligible for the study. Data was collected at the following study visits:Enrollment, Implant & Randomization, Pre-discharge (PDH) (≤ 72 hours post implant), Month 1 follow-up visit: 30 ± 14 days post implant, Month 3 follow-up visit: 90 ± 14 days post implant, Month 6 follow-up visit: 180 ± 14 days post implant and Month 12 follow-up visit: 365 ± 14 days post implant ;

Study Design

Related Conditions & MeSH terms

Bradycardia

Clinical Trial Details

NCT number	NCT01559311
Study type	Interventional
Source	Abbott Medical Devices
Contact
Status	Completed
Phase	N/A
Start date	February 2012
Completion date	April 2016

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03922386` - Safety and Electrical Performances of XFINE Leads	N/A
Completed	`NCT03294018` - Heart Rate Changes Following the Administration of Sugammadex
Not yet recruiting	`NCT05649891` - Checklists Resuscitation Emergency Department	N/A
Not yet recruiting	`NCT05440071` - PoSt-market Assessment on Safety and Performance of J-sHAPed xFINE Lead
Completed	`NCT02153242` - The Effects of Selective Site Right Ventricular Pacing
Recruiting	`NCT01825473` - Study of Erythromycin in GER-Associated Apnea of the Newborn	N/A
Completed	`NCT00950287` - Detection of Neonatal Bradycardia	N/A
Completed	`NCT00721136` - Randomized Study of the Use of Warfarin During Pacemaker or ICD Implantation in Patients Requiring Long Term Anticoagulation	N/A
Completed	`NCT00286858` - Beluga - Clinical Observations of Automatic Algorithms for Cardiac Pacing
Completed	`NCT00158925` - The EASYTRAK EPI Clinical Investigation	Phase 3
Completed	`NCT00180557` - Austria Study - Analysis of Difference Between Active and Passive Fixation Leads	Phase 4
Completed	`NCT01076348` - Model 4965 Post-Approval Study
Completed	`NCT04198220` - BIO\|STREAM.ICM Obesity
Recruiting	`NCT05298748` - The Effect of Womb Recordings on Maturation of Respiratory Control in Preterm Infants	N/A
Recruiting	`NCT04353960` - The Alaska Oculocardiac Reflex Study
Terminated	`NCT04093414` - Left Bundle Area Versus Selective His Bundle Pacing	N/A
Completed	`NCT03786640` - Abbott Brady 3T MRI PMCF
Recruiting	`NCT05935007` - Aveir DR Real-World Evidence Post-Approval Study
Recruiting	`NCT05932602` - AVEIR DR Coverage With Evidence Development (CED) Study
Recruiting	`NCT04075084` - Observation of Clinical Routine Care for Patients With BIOTRONIK Implantable Cardiac Monitors (ICMs)

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.